Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Phase 3 KarMMa-3 Trial Meets Primary End Point of PFS With Ide-Cel in R/R Multiple Myeloma
August 30th 2022Results from a pre-specified interim analysis of the phase 3 KarMMa-3 trial showed the primary end point of progression-free survival was met following treatment with idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma following 2 to 4 previous lines of therapy and who were refractory to their last treatment.
Clinically Meaningful Breast MRI Testing Burden Linked With Cancer Worry in Ductal Carcinoma in Situ
August 25th 2022Investigators stated that comprehending the quality of life reduction associated with MRI with or without mammography for patients with ductal carcinoma in situ may help to improve patient experience and help in the development of targeted strategies.
Laser Interstitial Thermal Therapy Appears to be a Promising Option in New, Recurrent Glioblastoma
August 23rd 2022Results from a multicenter study showed similar median overall survival results with laser interstitial thermal therapy compared with other tumor resection studies that used radiation and chemotherapy followed by laser ablation in patients with IDH wild-type glioblastoma.
FDA Approves Trastuzumab Deruxtecan in Unresectable or Metastatic HER2-Low Breast Cancer
August 5th 2022Based on results from the phase 3 DESTINY-Breast04 trial, the FDA has approved fam-trastuzumab deruxtecan-nxki as an intravenous infusion for patients with unresectable or metastatic HER2-low breast cancer.